About Us

Overview

Optieum Biotechnologies Inc. is a pre-clinical stage biotechnology company committed to developing innovative CAR-T cell therapies for treating patients with cancer.

Optieum’s proprietary platform technology, the Eumbody System, enables the development of advanced CAR constructs that optimize immune-cell function for oncology targets.

We are committed to helping patients with severe diseases by bringing life-changing therapies to those in need.

Optieum Biotechnologies Inc.

HQ: 454 Shitsukawa, Toon-shi, Ehime, Japan
Representative: Shun Nishioka
Foundation: 30 June , 2020

Technology

Eumbody System

Optieum Biotechnologies’ Eumbody System is a proprietary platform technology for developing next-generation CAR constructs.

The Eumbody System facilitates dynamic harmonization of the unique scFv sequence with CARs, enhancing the overall function of immune cells. This enhancement includes greater proliferation capacity and longevity, and enables superior reactivity against advanced tumors.

Partnering


Optieum Biotechnologies
has established a comprehensive intellectual
property portfolio to encompassing
CAR screening technologies.
To discuss a potential partnership
with Optieum Biotechnologies,
please contact Shun Nishioka
from the contact form below.

News Release

2022-12-13
Optieum Biotechnologies
Announcement of Research License and Option Agreement with GI CELL
Optieum Biotechnologies Inc., and GI CELL (HQ: Seongnam, Korea / CEO: Dr. Chun Pyo Hong) h[...]
2022-12-01
Optieum Biotechnologies
Optieum Biotechnologies and National Cancer Center Japan Signed Joint Research Agreement on Solid Tumor Targeting CAR-T Cell Programs
　We are pleased to announce that Optieum Biotechnologies Inc. (“Optieum”) has entere[...]
2022-01-27
Optieum Biotechnologies
Announcement of Grant Award from NEDO
　We are pleased to announce that Optieum Biotechnologies Inc. has been awarded “NEDO S[...]
2021-09-30
Optieum Biotechnologies
Optieum Biotechnologies Raises JPY 290 million ($ 2.6 million) in Seed Round Funding
　We are pleased to announce that Optieum Biotechnologies Inc. has raised JPY 290 million[...]
2021-03-19
Optieum Biotechnologies
Announcement of Research Collaboration with Daiichi-Sankyo
　We are pleased to announce that Optieum Biotechnologies Inc. has entered into a researc[...]
2021-03-02
Optieum Biotechnologies
Publication Announcement on Eumbody Sysem™
　We are pleased to announce that co-founder of Optieum Biotechnologies, Dr. Toshiki Ochi[...]

Contact Us